Plasma pancreatic polypeptide response to secretin

Area of Science:

• Gastroenterology
• Endocrinology
• Physiology

Background:

• Intravenous secretin is known to stimulate pancreatic polypeptide (PP) release in patients with endocrine enteropancreatic tumors.
• Data regarding secretin's effect on PP release in non-tumorous disorders are conflicting.
• Evaluation of plasma PP patterns after secretin administration is crucial for understanding gastroduodenal function.

Purpose of the Study:

• To investigate the plasma pancreatic polypeptide (PP) response to secretin administration in healthy subjects.
• To evaluate the PP pattern in patients with gastroduodenal diseases, specifically those with recurrent ulcer disease and/or hypergastrinemia.

Main Methods:

• Synthetic secretin was administered intravenously (2U/kg) to healthy volunteers and patients with Zollinger Ellison syndrome, duodenal ulcer, and atrophic gastritis.
• Blood samples were collected pre-injection and at 30-minute intervals post-injection.
• Plasma levels of pancreatic polypeptide (PP) and gastrin were quantified using radioimmunoassay.

Main Results:

• Secretin administration led to a prompt and significant increase in plasma PP levels across all subject groups (P<0.01).
• No significant differences were observed in peak PP values among the groups.
• No significant correlations were found between plasma PP and gastrin levels.

Conclusions:

• Pharmacological doses of secretin act as a potent stimulus for pancreatic polypeptide (PP) release.
• The study confirms secretin's efficacy in stimulating PP release, irrespective of the underlying gastroduodenal condition.